Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

36 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Drug Retention Rate and Causes of Discontinuation of Adalimumab in Uveitis: Real-World Data from the Biotherapies in Uveitis (BioÚvea) Study Group.
Llorenç V, Cordero-Coma M, Blanco-Esteban A, Heras-Mulero H, Losada-Castillo MJ, Jovani-Casano V, Valls-Pascual E, Jodar-Marquez M, García-Aparicio Á, Fonollosa A, González-Guijarro JJ, Rodriguez-Melian L, Fernández-Prada M, Jerez-Fidalgo M, Hernandez-Garfella M, Esquinas C, Sainz-de-la-Maza M, Adán A; Biotherapies in Uveitis (BioÚvea) Study Group. Llorenç V, et al. Ophthalmology. 2020 Jun;127(6):814-825. doi: 10.1016/j.ophtha.2019.11.024. Epub 2019 Dec 2. Ophthalmology. 2020. PMID: 31952883 Free article.
Adalimumab therapy for refractory uveitis: a pilot study.
Diaz-Llopis M, García-Delpech S, Salom D, Udaondo P, Hernández-Garfella M, Bosch-Morell F, Quijada A, Romero FJ. Diaz-Llopis M, et al. J Ocul Pharmacol Ther. 2008 Jun;24(3):351-61. doi: 10.1089/jop.2007.0104. J Ocul Pharmacol Ther. 2008. PMID: 18476805 Clinical Trial.
Anti-TNF-α therapy in patients with refractory uveitis due to Behçet's disease: a 1-year follow-up study of 124 patients.
Calvo-Río V, Blanco R, Beltrán E, Sánchez-Bursón J, Mesquida M, Adán A, Hernandez MV, Hernandez Garfella M, Valls Pascual E, Martínez-Costa L, Sellas-Fernández A, Cordero Coma M, Díaz-Llopis M, Gallego R, Salom D, García Serrano JL, Ortego N, Herreras JM, Fonollosa A, García-Aparicio AM, Maíz O, Blanco A, Torre I, Fernández-Espartero C, Jovani V, Peiteado-Lopez D, Pato E, Cruz J, Fernández-Cid C, Aurrecoechea E, García M, Caracuel MA, Montilla C, Atanes A, Hernandez FF, Insua S, González-Suárez S, Sánchez-Andrade A, Gamero F, Linares L, Romero-Bueno F, García AJ, Almodovar R, Minguez E, Carrasco Cubero C, Olive A, Vázquez J, Ruiz Moreno O, Jiménez-Zorzo F, Manero J, Muñoz Fernández S, Rueda-Gotor J, González-Gay MA. Calvo-Río V, et al. Rheumatology (Oxford). 2014 Dec;53(12):2223-31. doi: 10.1093/rheumatology/keu266. Epub 2014 Jul 4. Rheumatology (Oxford). 2014. PMID: 24996907
The effect of biologic therapy different from infliximab or adalimumab in patients with refractory uveitis due to Behçet's disease: results of a multicentre open-label study.
Santos-Gómez M, Calvo-Río V, Blanco R, Beltrán E, Mesquida M, Adán A, Cordero-Coma M, García-Aparicio ÁM, Valls Pascual E, Martínez-Costa L, Hernández MV, Hernandez Garfella M, González-Vela MC, Pina T, Palmou-Fontana N, Loricera J, Hernández JL, González-Gay MA. Santos-Gómez M, et al. Clin Exp Rheumatol. 2016 Sep-Oct;34(6 Suppl 102):S34-S40. Epub 2016 Apr 7. Clin Exp Rheumatol. 2016. PMID: 27054359
Development of an activity disease score in patients with uveitis (UVEDAI).
Pato E, Martin-Martinez MA, Castelló A, Méndez-Fernandez R, Muñoz-Fernández S, Cordero-Coma M, Martinez-Costa L, Valls E, Reyes M, Francisco F, Esteban M, Fonollosa A, Sanchez-Alonso F, Fernández-Espartero C, Diaz-Valle T, Carrasco JM, Beltran-Catalán E, Hernández-Garfella M, Hernández MV, Pelegrin L, Blanco R, Diaz-Valle D. Pato E, et al. Rheumatol Int. 2017 Apr;37(4):647-656. doi: 10.1007/s00296-016-3593-1. Epub 2016 Nov 4. Rheumatol Int. 2017. PMID: 27815703 Free PMC article.
Anti-interleukin 6 receptor tocilizumab in refractory uveitis associated with Behçet's disease: multicentre retrospective study.
Atienza-Mateo B, Calvo-Río V, Beltrán E, Martínez-Costa L, Valls-Pascual E, Hernández-Garfella M, Atanes A, Cordero-Coma M, Miquel Nolla J, Carrasco-Cubero C, Loricera J, González-Vela MC, Vegas-Revenga N, Fernández-Díaz C, Demetrio-Pablo R, Domínguez-Casas LC, Luis Martín-Varillas J, Palmou-Fontana N, Hernández JL, González-Gay MÁ, Blanco R. Atienza-Mateo B, et al. Rheumatology (Oxford). 2018 May 1;57(5):856-864. doi: 10.1093/rheumatology/kex480. Rheumatology (Oxford). 2018. PMID: 29471416
Anti-IL6-Receptor Tocilizumab in Refractory and Noninfectious Uveitic Cystoid Macular Edema: Multicenter Study of 25 Patients.
Vegas-Revenga N, Calvo-Río V, Mesquida M, Adán A, Hernández MV, Beltrán E, Valls Pascual E, Díaz-Valle D, Díaz-Cordovés G, Hernandez-Garfella M, Martínez-Costa L, Calvo I, Atanes A, Linares LF, Modesto C, González-Vela C, Demetrio-Pablo R, Aurrecoechea E, Cordero M, Domínguez-Casas LC, Atienza-Mateo B, Martín-Varillas JL, Loricera J, Palmou-Fontana N, Hernández JL, González-Gay MA, Blanco R. Vegas-Revenga N, et al. Am J Ophthalmol. 2019 Apr;200:85-94. doi: 10.1016/j.ajo.2018.12.019. Epub 2019 Jan 17. Am J Ophthalmol. 2019. PMID: 30660771 Free article.
Comparative Study of Infliximab Versus Adalimumab in Refractory Uveitis due to Behçet's Disease: National Multicenter Study of 177 Cases.
Atienza-Mateo B, Martín-Varillas JL, Calvo-Río V, Demetrio-Pablo R, Beltrán E, Sánchez-Bursón J, Mesquida M, Adan A, Hernández MV, Hernández-Garfella M, Valls-Pascual E, Martínez-Costa L, Sellas-Fernández A, Cordero-Coma M, Díaz-Llopis M, Gallego R, García-Serrano JL, Ortego-Centeno N, Herreras JM, Fonollosa A, Garcia-Aparicio ÁM, Maíz-Alonso O, Blanco A, Torre-Salaberri I, Fernandez-Espartero C, Jovaní V, Peiteado D, Pato E, Cruz J, Férnandez-Cid C, Aurrecoechea E, García-Arias M, Castañeda S, Caracuel-Ruiz MA, Montilla-Morales CA, Atanes-Sandoval A, Francisco F, Insua S, González-Suárez S, Sanchez-Andrade A, Gamero F, Linares Ferrando LF, Romero-Bueno F, García-González AJ, González RA, Muro EM, Carrasco-Cubero C, Olive A, Prior Á, Vázquez J, Ruiz-Moreno O, Jiménez-Zorzo F, Manero J, Muñoz Fernandez S, Fernández-Carballido C, Rubio-Romero E, Pages FA, Toyos-Sáenz de Miera FJ, Martinez MG, Díaz-Valle D, López Longo FJ, Nolla JM, Álvarez ER, Martínez MR, González-López JJ, Rodríguez-Cundin P, Hernández JL, González-Gay MA, Blanco R. Atienza-Mateo B, et al. Arthritis Rheumatol. 2019 Dec;71(12):2081-2089. doi: 10.1002/art.41026. Epub 2019 Oct 21. Arthritis Rheumatol. 2019. PMID: 31237427 Free article.
Long-term Follow-up and Optimization of Infliximab in Refractory Uveitis Due to Behçet Disease: National Study of 103 White Patients.
Martín-Varillas JL, Atienza-Mateo B, Calvo-Rio V, Beltrán E, Sánchez-Bursón J, Adán A, Hernández-Garfella M, Valls-Pascual E, Sellas-Fernández A, Ortego N, Maíz O, Torre I, Fernández-Espartero C, Jovani V, Peiteado D, Valle DD, Aurrecoechea E, Caracuel MA, García-González AJ, Álvarez ER, Vegas-Revenga N, Demetrio-Pablo R, Castañeda S, González-Gay MA, Hernández JL, Blanco R; Ricardo Blanco on behalf of the Spanish Collaborative Group of Refractory Behçet’s Disease. Martín-Varillas JL, et al. J Rheumatol. 2021 May;48(5):741-750. doi: 10.3899/jrheum.200300. Epub 2020 Oct 1. J Rheumatol. 2021. PMID: 33004539
Tocilizumab in Behçet's disease with refractory ocular and/or neurological involvement: response according to different clinical phenotypes.
Atienza-Mateo B, Beltrán E, Hernández-Garfella M, Valls Pascual E, Martínez-Costa L, Atanes A, Moriano C, Cordero-Coma M, Nolla JM, Carrasco Cubero C, Sánchez Martín J, Calvo-Río V, Demetrio R, Palmou-Fontana N, González-Gay MÁ, Blanco R. Atienza-Mateo B, et al. Among authors: hernandez garfella m. Clin Exp Rheumatol. 2021 Sep-Oct;39 Suppl 132(5):37-42. doi: 10.55563/clinexprheumatol/9ipkcs. Epub 2021 Apr 21. Clin Exp Rheumatol. 2021. PMID: 33886457 Free article.
36 results